menu

Current Standards and Future Opportunities for ADCs in Advanced/Metastatic Triple-Negative Breast Cancer

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Current Standards and Future Opportunities for ADCs in Advanced/Metastatic Triple-Negative Breast Cancer

4 chapters
Play All
0.50 credits
30 minutes
Chapter 1
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.50 credits
Completing the pre-test is required to view this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    Antibody-drug conjugates have transformed the treatment of triple-negative breast cancer (TNBC). Tune in to hear about approved ADCs and others in development and find out where they fit into the NCCN Guidelines for TNBC.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    William J. Gradishar, MD
    Robert H. Lurie Comprehensive Cancer Center
    Northwestern Medicine
    Chicago, IL

    Research funding: AstraZeneca, Gilead Sciences, Menarini, Merck, Novartis, Pfizer
    Consulting Fees: AstraZeneca, MacroGenics, Menarini, Pfizer

    Faculty:
    Javier Cortés, MD, PhD
    Head of Breast Cancer and Gynecological Cancers
    Hospital Universitario Ramón y Cajal
    Madrid, Spain

    Consultant or Advisory: AstraZeneca, Athenex, Bioasis, BioInvent, Boehringer Ingelheim, Celgene, Cellestia, Clovis Oncology, Daiichi Sankyo, Ellipses, Erytech, GEMoaB, Gilead, GlaxoSmithKline, HiberCell, Leuko, Lilly, Menarini, Merck Sharp & Dohme, Polyphor, Roche, Seagen Inc., Zymeworks
    Commercial Interest Speakers Bureau: Celgene, Daiichi Sankyo, Eisai, Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Samsung Bioepis
    Research funding: ARIAD Pharmaceuticals, AstraZeneca, Bayer Healthcare, Baxalta GmbH/Servier Affaires, Eisai, F. Hoffmann-La Roche, Guardant Health, Merck Sharp & Dohme, Pfizer, PIQUR Therapeutics, Puma Biotechnology, Roche
    Stock options: Nektar Therapeutics

    Hope S. Rugo, MD
    Professor of Medicine
    Director, Breast Oncology and Clinical Trials Education
    UCSF Helen Diller Family Comprehensive Cancer Center
    San Francisco, CA

    Research: Astellas, AstraZeneca, Daiichi Sankyo, Eli Lilly, Genentech/Roche, Gilead Sciences, Merck, Novartis, OBI, Pfizer, Seattle Genetics, Sermonix
    Consultant or Advisory: AstraZeneca, Blueprint Medicines, Napo, Puma Biotechnology
    Travel support to academic meetings: AstraZeneca, Gilead, Merck

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • Libby Lurwick has nothing to disclose.
    • Rosanne Strauss, PharmD, MBA, has nothing to disclose.
    • Anna Trentini has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Select appropriate immune-oncologic therapies based on the NCCN Clinical Practice Guideline recommendations
    • Apply strategies for the optimal management of adverse events related to antibody-drug conjugates
  • Target Audience

    This activity is designed to meet the educational needs of medical oncologists, pathologists, nurses, pharmacists, and other healthcare professionals involved in the treatment of patients with breast cancer globally.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC), the National Comprehensive Cancer Network® (NCCN®), and La Fundación ECO (ECO Foundation). GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credits to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu.

    Global Learning Collaborative (GLC) designates this Panel Discussion activity for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for .50 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for .50 AAPA Category 1 CME credits. Approval is valid until January 5, 2024. PAs should claim only the credit commensurate with the extent of their participation in the activity. 

    Global Learning Collaborative (GLC) designates this activity for 0.5 contact hours/0.05 CEUs of Pharmacy contact hours. 

    The Universal Activity Number for this program is JA0006235-0000-22-065-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net). 

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.

    Provided in Partnership with: 

  • Commercial Support

    This activity is supported by independent educational grants from Daiichi Sankyo, Inc. and Gilead Sciences.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    Antibody-drug conjugates have transformed the treatment of triple-negative breast cancer (TNBC). Tune in to hear about approved ADCs and others in development and find out where they fit into the NCCN Guidelines for TNBC.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    William J. Gradishar, MD
    Robert H. Lurie Comprehensive Cancer Center
    Northwestern Medicine
    Chicago, IL

    Research funding: AstraZeneca, Gilead Sciences, Menarini, Merck, Novartis, Pfizer
    Consulting Fees: AstraZeneca, MacroGenics, Menarini, Pfizer

    Faculty:
    Javier Cortés, MD, PhD
    Head of Breast Cancer and Gynecological Cancers
    Hospital Universitario Ramón y Cajal
    Madrid, Spain

    Consultant or Advisory: AstraZeneca, Athenex, Bioasis, BioInvent, Boehringer Ingelheim, Celgene, Cellestia, Clovis Oncology, Daiichi Sankyo, Ellipses, Erytech, GEMoaB, Gilead, GlaxoSmithKline, HiberCell, Leuko, Lilly, Menarini, Merck Sharp & Dohme, Polyphor, Roche, Seagen Inc., Zymeworks
    Commercial Interest Speakers Bureau: Celgene, Daiichi Sankyo, Eisai, Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Samsung Bioepis
    Research funding: ARIAD Pharmaceuticals, AstraZeneca, Bayer Healthcare, Baxalta GmbH/Servier Affaires, Eisai, F. Hoffmann-La Roche, Guardant Health, Merck Sharp & Dohme, Pfizer, PIQUR Therapeutics, Puma Biotechnology, Roche
    Stock options: Nektar Therapeutics

    Hope S. Rugo, MD
    Professor of Medicine
    Director, Breast Oncology and Clinical Trials Education
    UCSF Helen Diller Family Comprehensive Cancer Center
    San Francisco, CA

    Research: Astellas, AstraZeneca, Daiichi Sankyo, Eli Lilly, Genentech/Roche, Gilead Sciences, Merck, Novartis, OBI, Pfizer, Seattle Genetics, Sermonix
    Consultant or Advisory: AstraZeneca, Blueprint Medicines, Napo, Puma Biotechnology
    Travel support to academic meetings: AstraZeneca, Gilead, Merck

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • Libby Lurwick has nothing to disclose.
    • Rosanne Strauss, PharmD, MBA, has nothing to disclose.
    • Anna Trentini has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Select appropriate immune-oncologic therapies based on the NCCN Clinical Practice Guideline recommendations
    • Apply strategies for the optimal management of adverse events related to antibody-drug conjugates
  • Target Audience

    This activity is designed to meet the educational needs of medical oncologists, pathologists, nurses, pharmacists, and other healthcare professionals involved in the treatment of patients with breast cancer globally.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC), the National Comprehensive Cancer Network® (NCCN®), and La Fundación ECO (ECO Foundation). GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credits to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu.

    Global Learning Collaborative (GLC) designates this Panel Discussion activity for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for .50 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for .50 AAPA Category 1 CME credits. Approval is valid until January 5, 2024. PAs should claim only the credit commensurate with the extent of their participation in the activity. 

    Global Learning Collaborative (GLC) designates this activity for 0.5 contact hours/0.05 CEUs of Pharmacy contact hours. 

    The Universal Activity Number for this program is JA0006235-0000-22-065-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net). 

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.

    Provided in Partnership with: 

  • Commercial Support

    This activity is supported by independent educational grants from Daiichi Sankyo, Inc. and Gilead Sciences.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule31 Jan 2023